Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women.

BACKGROUND Postmenopausal estrogen therapy has favorable effects on serum lipoproteins in women with normal serum lipid levels, but the effect of combined estrogen and progestin therapy on lipoproteins in women with hypercholesterolemia has not been determined, nor has it been directly compared with the effect of conventional lipid-lowering therapy. METHODS In a randomized crossover trial, we studied 58 postmenopausal women with fasting serum total cholesterol levels greater than 250 mg per deciliter. Each woman received simvastatin (10 mg daily) for eight weeks and postmenopausal hormone therapy (up to 1.25 mg of conjugated equine estrogens daily, along with 5 mg of medroxyprogesterone acetate daily) for eight weeks, with an eight-week washout period between the two treatment phases. RESULTS At base line, the mean (+/-SD) cholesterol values were as follows: total cholesterol, 305+/-39 mg per deciliter; high-density lipoprotein (HDL) cholesterol, 62+/-19 mg per deciliter; and low-density lipoprotein (LDL) cholesterol, 217+/-39 mg per deciliter. For total cholesterol, the mean decrease with hormone therapy was 14 percent (95 percent confidence interval, 11 to 16 percent) and the mean decrease with simvastatin was 26 percent (95 percent confidence interval, 23 to 29 percent). For LDL cholesterol, the mean decrease was 24 percent (95 percent confidence interval, 20 to 28 percent) with hormone therapy and 36 percent (95 percent confidence interval, 32 to 40 percent) with simvastatin. The effect of simvastatin was significantly greater than that of hormone therapy (P<0.001). HDL cholesterol increased similarly with hormone therapy (mean increase, 7 percent; 95 percent confidence interval, 2 to 12 percent) and simvastatin (mean increase, 7 percent; 95 percent confidence interval, 4 to 10 percent). Triglyceride levels increased with hormone therapy (mean increase, 29 percent; 95 percent confidence interval, 15 to 42 percent) but decreased with simvastatin (mean decrease, 14 percent; 95 percent confidence interval, 8 to 20 percent). Lp(a) lipoprotein decreased with hormone therapy (mean decrease, 27 percent; 95 percent confidence interval, 20 to 34 percent), but not with simvastatin. CONCLUSIONS In postmenopausal women with hypercholesterolemia, therapy with estrogen plus progestin has beneficial effects on lipoprotein levels. Hormone therapy may be an effective alternative to treatment with simvastatin, especially in women with normal triglyceride levels.

[1]  L. Testolin,et al.  Effects of conjugated estrogens alone and combined with pravastatin for management of hypercholesterolemia in postmenopausal women , 1996 .

[2]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[3]  S. Tonstad,et al.  Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolemia among postmenopausal women , 1995, Journal of internal medicine.

[4]  M. Denke,et al.  Effects of continuous combined hormone-replacement therapy on lipid levels in hypercholesterolemic postmenopausal women. , 1995, The American journal of medicine.

[5]  F. Leus,et al.  Influence of apolipoprotein(a) phenotype on lipoprotein(a) quantification: evaluation of three methods. , 1994, Clinical biochemistry.

[6]  R. Muche,et al.  Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS) , 1994, European journal of clinical investigation.

[7]  C. Glueck,et al.  Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein[a]. , 1994, The Journal of laboratory and clinical medicine.

[8]  F. Sacks,et al.  Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. , 1994, Archives of internal medicine.

[9]  Y. Min,et al.  Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[10]  M. Klag,et al.  Plasma lipoprotein levels as predictors of cardiovascular death in women. , 1993, Archives of internal medicine.

[11]  P. Crosignani,et al.  The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women. , 1993, Archives of internal medicine.

[12]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[13]  J. Ordovás,et al.  Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. , 1992, Metabolism: clinical and experimental.

[14]  S. Yusuf,et al.  Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.

[15]  P. Nestel,et al.  Diet and coronary heart disease. The National Heart Foundation of Australia. , 1992, The Medical journal of Australia.

[16]  M. Pike,et al.  A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. , 1992, Atherosclerosis.

[17]  R. Lobo,et al.  Clinical review 27: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. , 1991, The Journal of clinical endocrinology and metabolism.

[18]  B. Rosner,et al.  Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. , 1991, The New England journal of medicine.

[19]  J. F. Barnes,et al.  Lipoprotein (a) concentrations in postmenopausal women taking norethisterone. , 1991, BMJ.

[20]  J. Manson,et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.

[21]  M. Austin.  Plasma triglyceride and coronary heart disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[22]  D. Mirvis,et al.  Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. , 1990, Archives of internal medicine.

[23]  C. Christiansen,et al.  Influence of menopause on serum lipids and lipoproteins. , 1990, Maturitas.

[24]  D R Jacobs,et al.  High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. , 1990, American journal of epidemiology.

[25]  K. Matthews,et al.  Menopause and Risk Factors for Coronary Heart Disease , 1989 .

[26]  C. Fletcher,et al.  Lipoprotein and apolipoprotein levels in postmenopausal women on continuous oestrogen/ progestogen therapy , 1989, British journal of obstetrics and gynaecology.

[27]  R. J. Hayes,et al.  Methods for assessing whether change depends on initial value. , 1988, Statistics in medicine.

[28]  W. Kannel.  Metabolic risk factors for coronary heart disease in women: perspective from the Framingham study , 1987 .

[29]  E. Barrett-Connor,et al.  Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. , 1987, Circulation.

[30]  V. Armstrong,et al.  The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. , 1986, Atherosclerosis.

[31]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[32]  A. Gotto,et al.  CORONARY ARTERY DISEASE Association of levels of lipoprotein Lp ( a ) , plasma lipids , and other lipoproteins with coronary artery disease documented by angiography , 2022 .

[33]  W. Gruber,et al.  Reagent for the Enzymatic Determination of Serum Total Triglycerides with Improved Lipolytic Efficiency , 1984, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[34]  R. Deeg,et al.  Kinetic enzymic method for automated determination of total cholesterol in serum. , 1983, Clinical chemistry.

[35]  P. Demacker,et al.  A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. , 1980, Clinical chemistry.

[36]  N. Blomqvist.  On the Relation between Change and Initial Value , 1977 .

[37]  G. Cutter.  Some Examples for Teaching Regression Toward the Mean from a Sampling Viewpoint , 1976 .

[38]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.